Overview

Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease

Status:
Unknown status
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
Treatment for no-option heart patients with coronary artery disease. Procedure includes the injection into the heart of a protein growth factor, administered by the Cordis Corp. MyoStar injection catheter, to stimulate the growth of blood vessels around blocked coronary arteries.
Phase:
Phase 2
Details
Lead Sponsor:
CardioVascular BioTherapeutics, Inc.
Treatments:
Mitogens